| ［1］ |
Bray F，Laversanne M，Sung H，et al. Global cancer statistics 2022： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin，2024，74（3）： 229-263.
|
| ［2］ |
Anderson WF，Katki HA，Rosenberg PS. Incidence of breast cancer in the United States： current and future trends［J］. J Natl Cancer Inst，2011，103（18）： 1397-1402.
|
| ［3］ |
Anderson WF，Rosenberg PS，Petito L，et al. Divergent estrogen receptor‐positive and ‐negative breast cancer trends and etiologic heterogeneity in Denmark［J］. Int J Cancer，2013，133（9）： 2201-2206.
|
| ［4］ |
Sung H，Devi BCR，Tang TS，et al. Divergent breast cancer incidence trends by hormone receptor status in the state of Sarawak，Malaysia［J］. Int J Cancer，2020，147（3）： 829-837.
|
| ［5］ |
Spring LM，Fell G，Arfe A，et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival： a comprehensive meta-analysis［J］. Clin Cancer Res，2020，26（12）： 2838-2848.
|
| ［6］ |
Preece PE，Wood RA，Mackie CR，et al. Tamoxifen as initial sole treatment of localised breast cancer in elderly women： a pilot study.［J］. BMJ，1982，284（6319）： 869-870.
|
| ［7］ |
Robertson JFR，Todd JH，Elston CW，et al. Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer［J］. BMJ，1988，297（6647）： 511-514.
|
| ［8］ |
Mustacchi G，Ceccherini R，Milani S，et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly： long-term results of the phase Ⅲ randomized controlled multicenter GRETA trial［J］. Ann Oncol，2003，14（3）： 414-420.
|
| ［9］ |
Ellis MJ，Tao Y，Luo J，et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics［J］. J Natl Cancer Inst，2008，100（19）： 1380-1388.
|
| ［10］ |
Smith IE，Dowsett M，Ebbs SR，et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole，tamoxifen，or both in combination： the immediate preoperative anastrozole，tamoxifen，or combined with tamoxifen （IMPACT） multicenter double blind randomized trial［J］. J Clin Oncol，2005，23（22）： 5108-5116.
|
| ［11］ |
Cataliotti L，Buzdar AU，Noguchi S，et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in post menopausal women with hormone receptor‐positive breast cancer： the pre‐operative “arimidex” compared to tamoxifen （PROACT）trial［J］. Cancer，2006，106（10）： 2095-2103.
|
| ［12］ |
Hunt KK，Suman VJ，Wingate HF，et al. Local-Regional recurrence after neoadjuvant endocrine therapy： data from ACOSOG Z1031 （Alliance），a randomized phase 2 neoadjuvant comparison between letrozole，anastrozole，and exemestane for postmenopausal women with estrogen receptor-positive clinical stage 2 or 3 breast cancer［J］. Ann Surg Oncol，2023，30（4）： 2111-2118.
|
| ［13］ |
Ellis MJ，Suman VJ，Hoog J，et al. Randomized Phase Ⅱ neoadjuvant comparison between letrozole，anastrozole，and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer： clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031［J］. J Clin Oncol，2011，29（17）： 2342-2349.
|
| ［14］ |
Lerebours F，Pulido M，Fourme E，et al. Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy： pooled analysis of two phase 2 trials［J］. Br J Cancer，2020，122（6）： 759-765.
|
| ［15］ |
Lerebours F，Rivera S，Mouret‐Reynier M，et al. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal，estrogen receptor-positive，human epidermal growth factor receptor 2-negative breast cancer patients： results of the UNICANCER CARMINA 02 French trial （UCBG 0609）［J］. Cancer，2016，122（19）： 3032-3040.
|
| ［16］ |
Quenel-Tueux N，Debled M，Rudewicz J，et al. Clinical and genomic analysis of a randomised phase Ⅱ study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer［J］. Br J Cancer，2015，113（4）： 585-594.
|
| ［17］ |
Ma CX，Suman VJ，Sanati S，et al. Endocrine-sensitive disease rate in postmenopausal patients with estrogen receptor-rich/ERBB2-negative breast cancer receiving neoadjuvant anastrozole，fulvestrant，or their combination： a phase 3 randomized clinical trial［J］. JAMA Oncology，2024，10（3）： 362.
|
| ［18］ |
Elias AD，Staley AW，Fornier M，et al. Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancer［J］. NPJ Breast Cancer，2024，10（1）： 88.
|
| ［19］ |
Hurvitz SA，Martin M，Press MF，et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH，phase Ⅱ neoadjuvant study in HR+/HER2− breast cancer［J］. Clin Cancer Res，2020，26（3）： 566-580.
|
| ［20］ |
Delaloge S，Dureau S，D’Hondt V，et al. Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer［J］. Eur J Cancer，2022，166： 300-308.
|
| ［21］ |
Cottu P，D’Hondt V，Dureau S，et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer［J］. Ann Oncol，2018，29（12）： 2334-2340.
|
| ［22］ |
Prat A，Saura C，Pascual T，et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive，HER2-negative，luminal B breast cancer （CORALLEEN）： an open-label，multicentre，randomised，phase 2 trial［J］. Lancet Oncol，2020，21（1）： 33-43.
|
| ［23］ |
André F，Ciruelos EM，Juric D，et al. Alpelisib plus fulvestrant for PIK3CA-mutated，hormone receptor-positive，human epidermal growth factor receptor-2-negative advanced breast cancer： final overall survival results from SOLAR-1［J］. Ann Oncol，2021，32（2）： 208-217.
|
| ［24］ |
Saura C，Hlauschek D，Oliveira M，et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive，HER2-negative，early-stage breast cancer （LORELEI）： a multicentre，randomised，double-blind，placebo-controlled，phase 2 trial［J］. Lancet Oncol，2019，20（9）： 1226-1238.
|
| ［25］ |
Fimereli D，Nuciforo PG，De Azambuja E，et al. 10P PIK3CA mutation and response to neoadjuvant taselisib and endocrine therapy： a biomarker study of the LORELEI trial［J］. ESMO Open，2024，9： 103019.
|
| ［26］ |
Oliveira M，Falato C，Cejalvo J M，et al. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer： final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study［J］. Ann Oncol，2023，34（8）： 670-680.
|
| ［27］ |
Oliveira M，Pascual T，Parraga KA，et al. Primary results of SOLTI VALENTINE： neoadjuvant randomized phase Ⅱ trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive （HR+）/HER2-negative （neg） early breast cancer （EBC）［J］. Clin Cancer Res，2025，31（12）:615.
|
| ［28］ |
Zhao H，Li D，Li Q，et al. Tucidinostat plus exemestane as a neoadjuvant in early-stage，hormone receptor-positive，human epidermal growth factor receptor 2-negative breast cancer［J］. Oncologist，2024，29（6）： e763-e770.
|
| ［29］ |
Vaklavas C，Roberts BS，Varley KE，et al. TBCRC 002： a phase Ⅱ，randomized，open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer［J］. Breast Cancer Res，2020，22（1）： 22.
|
| ［30］ |
Vaklavas C，Stringer-Reasor EM，Elkhanany AM，et al. A phase Ⅰ/Ⅱ study of preoperative letrozole，everolimus，and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer［J］. Breast Cancer Res Treat，2023，198（2）： 217-229.
|
| ［31］ |
Loi S，Curigliano G，Salgado RF，et al. LBA20 A randomized，double-blind trial of nivolumab （NIVO） vs placebo （PBO） with neoadjuvant chemotherapy （NACT） followed by adjuvant endocrine therapy （ET） ± NIVO in patients （pts） with high-risk，ER+ HER2- primary breast cancer （BC）［J］. Ann Oncol，2023，34： S1259-S1260.
|
| ［32］ |
Cardoso F，McArthur HL，Schmid P，et al. LBA21 KEYNOTE-756： Phase Ⅲ study of neoadjuvant pembrolizumab （pembro） or placebo （pbo） + chemotherapy （chemo），followed by adjuvant pembro or pbo + endocrine therapy （ET） for early-stage high-risk ER+/HER2- breast cancer［J］. Ann Oncol，2023，34： S1260-S1261.
|
| ［33］ |
Chen L，Wu W，Liang F，et al. A prospective，phase Ⅱ，neoadjuvant study based on chemotherapy sensitivity in HR+/HER2‐ breast cancer‐FINEST study［J］. Cancer Commun （Lond），2025，45（4）： 411-421.
|
| ［34］ |
Wolmark N，Wang J，Mamounas E，et al. Preoperative chemotherapy in patients with operable breast cancer： nine-year results from national surgical adjuvant breast and bowel project B-18［J］. Jnci Monographs，2001，2001（30）：96-102.
|
| ［35］ |
Bear HD，Anderson S，Smith RE，et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer： national surgical adjuvant breast and bowel project protocol B-27［J］. J Clin Oncol，2006，24（13）： 2019-2027.
|
| ［36］ |
中国抗癌协会乳腺癌专业委员会，中华医学会肿瘤学分会乳腺肿瘤学组. 乳腺癌诊治指南与规范：2025年版精要本［EB/OL］. （2024-12-22） ［2024-12-30］.
|
| ［37］ |
Gluz O，Kuemmel S，Nitz U，et al. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+ /HER2− early breast cancer： results from the neoadjuvant part of the WSG-ADAPT-HR+ /HER2-trial［J］. Ann Oncol，2023，34（6）： 531-542.
|
| ［38］ |
Asselain B，Barlow W，Bartlett J，et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer： meta-analysis of individual patient data from ten randomised trials［J］. Lancet Oncol，2018，19（1）： 27-39.
|
| ［39］ |
Wang Y，He L，Song Y，et al. The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy： a meta-analysis［J］. BMC Women's Health，2020，20（1）： 17.
|
| ［40］ |
Devaux A，Beniuga G，Quaghebeur C，et al. Abstract P4-07-16： B-IMMUNE final analysis： a phase Ⅰb/Ⅱ study of durvalumab combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2 （-） or triple negative breast cancers［J］. Cancer Res，2023，83（5 Suppl）： P4-7-16.
|
| ［41］ |
Gogate A，Ranjan S，Kumar A，et al. Correlation between pathologic complete response，event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer［J］. Front Oncol，2023，13： 1119102.
|
| ［42］ |
Symmans WF，Wei C，Gould R，et al. Long-Term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype［J］. J Clin Oncol，2017，35（10）： 1049-1060.
|
| ［43］ |
Symmans WF，Yau C，Chen YY，et al. Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer： an analysis of data from the I-SPY2 randomized clinical trial［J］. JAMA Oncol，2021，7（11）： 1654.
|
| ［44］ |
Liang Q，Ma D，Gao RF，et al. Effect of Ki-67 expression levels and histological grade on breast cancer early relapse in patients with different immunohistochemical-based subtypes［J］. Sci Rep，2020，10（1）： 7648.
|
| ［45］ |
Dowsett M，Smith IE，Ebbs SR，et al. Short-Term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival［J］. Clin Cancer Res, 2005，11（2 Pt 2）：951s-958s.
|
| ［46］ |
Smith I，Robertson J，Kilburn L，et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer （POETIC）： an open-label，multicentre，parallel-group，randomised，phase 3 trial［J］. Lancet Oncol，2020，21（11）： 1443-1454.
|
| ［47］ |
Martins-Branco D，Nader-Marta G，Molinelli C，et al. Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer： a systematic review and meta-analysis［J］. Eur J Cancer，2023，194： 113358.
|
| ［48］ |
Ellis MJ，Suman VJ，Hoog J，et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer： results from the American College of Surgeons Oncology Group Z1031 trial （Alliance）［J］. J Clin Oncol，2017，35（10）： 1061-1069.
|
| ［49］ |
Ma CX，Suman V，Leitch AM，et al. ALTERNATE： neoadjuvant endocrine treatment （NET） approaches for clinical stage Ⅱ or Ⅲ estrogen receptor-positive HER2-negative breast cancer （ER+ HER2- BC） in postmenopausal （PM） women： alliance A011106［J］. J Clin Oncol, 2020，38： 504.
|
| ［50］ |
Abdelsattar JM，Al-Hilli Z，Hoskin TL，et al. Validation of the CPS+EG staging system for disease-specific survival in breast cancer patients treated with neoadjuvant chemotherapy［J］. Ann Surg Oncol，2016，23（10）： 3206-3211.
|
| ［51］ |
Roussot N，Constantin G，Desmoulins I，et al. Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy［J］. Eur J Cancer，2024，202： 114037.
|
| ［52］ |
Marmé F，Martin M，Untch M，et al. Palbociclib combined with endocrine treatment in hormone receptor-positive，HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy： subgroup analyses of premenopausal patients in PENELOPE-B［J］. ESMO Open，2024，9（6）： 103466.
|
| ［53］ |
Iwata H，Masuda N，Yamamoto Y，et al. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+，HER2-negative breast cancer： the TransNEOS study［J］. Breast Cancer Res Treat，2019，173（1）： 123-133.
|
| ［54］ |
Davey MG，Ryan ÉJ，Boland MR，et al. Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer： a systematic review and meta-analysis［J］. Breast，2021，58： 113-120.
|
| ［55］ |
Boland MR，Al-Maksoud A，Ryan ÉJ，et al. Value of a 21-gene expression assay on core biopsy to predict neoadjuvant chemotherapy response in breast cancer： systematic review and meta-analysis［J］. Br J Surg，2021，108（1）： 24-31.
|
| ［56］ |
Whitworth P，Beitsch P，Mislowsky A，et al. Chemosensitivity and endocrine sensitivity in clinical luminal breast cancer patients in the prospective neoadjuvant breast registry symphony trial （NBRST） predicted by molecular subtyping［J］. Ann Surg Oncol，2017，24（3）： 669-675.
|
| ［57］ |
Huppert LA，Wolf D，Yau C，et al. Pathologic complete response （pCR） rates for patients with HR+/HER2- high-risk，early-stage breast cancer （EBC） by clinical and molecular features in the phase Ⅱ I-SPY2 clinical trial［J］. Ann Oncol，2025，36（2）：172-184.
|
| ［58］ |
Ohara AM，Naoi Y，Shimazu K，et al. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer［J］. Breast Cancer Res Treat，2019，173（3）： 533-543.
|